$114.13 0.6%
BNTX Stock Price vs. AI Score
Data gathered: December 26

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - BioNTech (BNTX)

Analysis generated January 31, 2024. Powered by Chat GPT.

BioNTech SE is a German biotechnology company known for developing a range of patient-specific immunotherapies for cancer and other diseases. Co-founded by Ugur Sahin and Ozlem Tureci, BioNTech gained international recognition through its collaboration with Pfizer in developing one of the first widely authorized mRNA COVID-19 vaccines. The company operates in a rapidly evolving industry characterized by intense research and development, advanced technology platforms, and a growing pipeline of therapeutic and vaccine candidates.

Read full AI stock Analysis

Stock Alerts - BioNTech (BNTX)

company logo BioNTech | December 18
Price is down by -5.5% in the last 24h.
company logo BioNTech | December 17
Employee Rating is down by 3% over the last month.
company logo BioNTech | December 17
Business Outlook among employees is down by 10.2% over the last month.
company logo BioNTech | December 16
Price is down by -5.7% in the last 24h.

About BioNTech

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.


BioNTech
Price $114.13
Target Price Sign up
Volume 131,610
Market Cap $27.4B
Year Range $78.36 - $124.71
Dividend Yield 0%
PE Ratio 160.8
Analyst Rating 76% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '241.24B179M1.07B198M211M0.880
Q2 '24129M60M69M-808M-749M-3.360
Q1 '24188M59M129M-315M-289M-1.410
Q4 '231.48B179M1.3B458M507M1.900
Q3 '231.48B179M1.3B458M456M0.670

Insider Transactions View All

No recorded Insider transactions.

Congress Trading View All

Politician Filing Date Type Size
Joshua Gottheimer
Democrat
May 15, 24 Buy $1K - $15K
Joshua Gottheimer
Democrat
Apr 7, 24 Sell $1K - $15K
Joshua Gottheimer
Democrat
Jan 7, 24 Buy $1K - $15K

What is the Market Cap of BioNTech?

The Market Cap of BioNTech is $27.4B.

What is BioNTech's PE Ratio?

As of today, BioNTech's PE (Price to Earnings) ratio is 160.8.

What is the current stock price of BioNTech?

Currently, the price of one share of BioNTech stock is $114.13.

How can I analyze the BNTX stock price chart for investment decisions?

The BNTX stock price chart above provides a comprehensive visual representation of BioNTech's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BioNTech shares. Our platform offers an up-to-date BNTX stock price chart, along with technical data analysis and alternative data insights.

Does BNTX offer dividends to its shareholders?

As of our latest update, BioNTech (BNTX) does not offer dividends to its shareholders. Investors interested in BioNTech should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of BioNTech?

Some of the similar stocks of BioNTech are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.